Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) was down 3% during mid-day trading on Monday. The stock traded as low as $23.0750 and last traded at $23.55. 124,512 shares were traded during mid-day trading, an increase of 149% from the average session volume of 50,104 shares. The stock had previously closed at $24.28.
Neoleukin Therapeutics Stock Up 14.7%
The firm has a 50 day moving average price of $31.26 and a 200-day moving average price of $27.54. The stock has a market capitalization of $253.65 million, a PE ratio of -8.68 and a beta of 1.11.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc was a biotechnology company focused on designing and developing computationally engineered immunotherapies for cancer and other serious diseases. The company used protein-engineering technologies to create novel cytokine therapies intended to stimulate the immune system while addressing limitations associated with naturally occurring cytokines.
Its leading product candidate was NL-201, a de novo protein designed to selectively activate pathways associated with interleukin-2 and interleukin-15.
Recommended Stories
- Five stocks we like better than Neoleukin Therapeutics
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
